Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,600.80
(
0.23%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
93.86
(
2.74%
)
Bitcoin
72,739.29
(
-1.11%
)
News Focus
News Focus
Post# of 828440
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ATLnsider

Send PM Follow Ignore
Followers 175
Posts 3513
Boards Moderated 1
Alias Born 11/03/2014

ATLnsider

Re: eagle8 post# 744963

Thursday, 01/23/2025 8:42:57 AM

Thursday, January 23, 2025 8:42:57 AM

Post# of 828440
This puts Bristol Myers Squibb (BMY) in play, as a potential combination partner, with an already regulatory approved DCVax “complementary agent”.

BMY has the most popular, FDA approved CTLA-4 checkpoint inhibitor on the market now, Ipilimumab (Yervoy).
Bullish
Bullish

This is a PSA to all manipulative and collusive Market Makers, Hedge Funds and Short Sellers:

TIME IS RUNNING OUT. THE CLOCK IS TICKING!!!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News